C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Purchases New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 4,712 shares of the company’s stock, valued at approximately $104,000.

Several other hedge funds have also added to or reduced their stakes in TEVA. Creative Planning boosted its holdings in Teva Pharmaceutical Industries by 4.5% during the third quarter. Creative Planning now owns 42,815 shares of the company’s stock worth $772,000 after buying an additional 1,863 shares during the last quarter. Blue Trust Inc. boosted its holdings in Teva Pharmaceutical Industries by 40.1% during the third quarter. Blue Trust Inc. now owns 14,619 shares of the company’s stock worth $263,000 after buying an additional 4,185 shares during the last quarter. Raymond James & Associates boosted its holdings in Teva Pharmaceutical Industries by 25.1% during the third quarter. Raymond James & Associates now owns 1,020,719 shares of the company’s stock worth $18,393,000 after buying an additional 204,775 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after buying an additional 805 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after buying an additional 1,094 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.55% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TEVA shares. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Trading Down 0.8 %

NYSE TEVA opened at $17.02 on Friday. The firm has a market cap of $19.28 billion, a P/E ratio of -11.73, a P/E/G ratio of 1.34 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock’s 50-day moving average is $19.92 and its 200-day moving average is $18.48. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.